Antonio CPA - Cytodyn Treasurer CFO
| CYDY Stock | USD 0.11 0.01 8.33% |
Insider
Antonio CPA is Treasurer CFO of Cytodyn
| Age | 40 |
| Phone | 360 980 8524 |
| Web | https://www.cytodyn.com |
Cytodyn Management Efficiency
The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| James Levine | Cardiff Oncology | 53 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Tod Smeal | Cardiff Oncology | 59 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| William JD | Akero Therapeutics | 51 | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Mark Erlander | Cardiff Oncology | 64 | |
| Vicki Kelemen | Cardiff Oncology | N/A | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
Management Performance
| Return On Asset | -1.48 |
Cytodyn Leadership Team
Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bernie PMP, VP Operations | ||
| George Bitar, Head Director | ||
| Denis Burger, Vice Chairman and Chief Science Officer | ||
| Antonio CPA, Treasurer CFO | ||
| Kush Dhody, VP Operations | ||
| Cyrus MBA, President | ||
| Cristina Leon, Investors |
Cytodyn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.48 | |||
| Current Valuation | 286.7 M | |||
| Shares Outstanding | 832.97 M | |||
| Shares Owned By Insiders | 7.91 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Price To Earning | (3.14) X | |||
| Price To Book | 1,066 X | |||
| Price To Sales | 1,174 X | |||
| Revenue | 266 K | |||
| Gross Profit | (73.28 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cytodyn OTC Stock Analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.